TCRX today
$0.17-$0.02 (-10.18%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourAscending Triangle
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $0.25
Key levels
Resistance$0.20
Resistance$0.17
Latest news & SEC filings
EarningsTScan Therapeutics posts wider quarterly loss, revenue tops view
SEC FilingTScan Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All TCRX news →About TScan Therapeutics
TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its product candidates are created using a non-viral transposon/transposase platform and are being studied in clinical trials. The company also operates an internal manufacturing facility for clinical production and relies on third parties for certain components. It operates in the United States.
Based on the company's 10-K filed Mar 4, 2026.
Nasdaq · Healthcare
TScan Therapeutics, Inc. (TCRX)
What Is the Price Target for TCRX?
SEPT Low Target
$1.00
SEPT Mid Target
$1.00
SEPT High Target
$1.00
Analyst Consensus
$1.00
Is TCRX a Buy or Sell Right Now?
Thesis
- •Revenue growing 266.6% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TCRX.
Start Free Trial →Is TCRX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$1.09
22
Moat Score
NONE
2/9
Piotroski Score
-4.1
Altman Z-Score
What Is Smart Money Doing with TCRX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| MacBeath Gavin | director officer | Buy | 1,000,000 | - | Oct 1, 2026 |
| ZDRAVESKI ZORAN | officer | Buy | 300,000 | - | Oct 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TCRX Growth Story
Revenue YoY
266.6%
3yr Revenue CAGR
-8.6%
EPS Growth YoY
12.28%
FCF Growth YoY
-21.9%
Revenue Trend
ACCELERATING
Dark Pool Trades for TCRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for TCRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:54:35 | $0.17 | 1,400 | $$236 | SELL |
| 19:54:30 | $0.17 | 1,400 | $$236 | SELL |
| 19:54:30 | $0.17 | 5,000 | $$842 | SELL |
| 19:54:30 | $0.17 | 1,000 | $$170 | SELL |
| 19:46:05 | $0.17 | 1,000 | $$172 | SELL |
5 dark pool trades shown · $$2K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for TScan Therapeutics, Inc. (TCRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TCRX — frequently asked questions
What is TCRX stock price today?
TScan Therapeutics, Inc. (TCRX) is at $0.17, down 10.18% (-$0.02) at the Nov 12, 2026 close.
Why is TCRX stock moving today?
Latest TCRX news — Nov 12, 2026: TScan Therapeutics posts wider quarterly loss, revenue tops view · Nov 12, 2026: TScan Therapeutics, Inc. filed a report on a major company event (Form 8-K)
What is the TCRX price target?
The average analyst price target for TCRX is $1.00, ranging from $1 to $1, based on 3 analysts. Latest: HC Wainwright & Co. downgrade on Sep 8, 2026.
What do analysts rate TCRX?
Analyst ratings for TCRX: 0 Buy, 3 Hold, 3 Sell — consensus Hold.
Did TCRX beat earnings?
TCRX last reported on Aug 12, 2026: EPS -$0.23 vs -$0.25 expected — a beat of 9.2%.
Does TCRX pay a dividend?
TCRX does not currently pay a dividend.
How much debt does TCRX have?
TScan Therapeutics, Inc. reported $33M of debt and $100M of cash (Jun 30, 2026).
What are TCRX support and resistance levels?
Resistance: $0.17, $0.20, $0.25.
What are insiders doing with TCRX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on TCRX?
Nov 12, 2026: TScan Therapeutics posts wider quarterly loss, revenue tops view · Nov 12, 2026: TScan Therapeutics, Inc. filed a report on a major company event (Form 8-K)